CN112703009B - 治疗急性肺损伤的组合物和方法 - Google Patents

治疗急性肺损伤的组合物和方法 Download PDF

Info

Publication number
CN112703009B
CN112703009B CN201980060751.3A CN201980060751A CN112703009B CN 112703009 B CN112703009 B CN 112703009B CN 201980060751 A CN201980060751 A CN 201980060751A CN 112703009 B CN112703009 B CN 112703009B
Authority
CN
China
Prior art keywords
pip
lps
lung
mice
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060751.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112703009A (zh
Inventor
A·B·费舍尔
S·I·范斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CN112703009A publication Critical patent/CN112703009A/zh
Application granted granted Critical
Publication of CN112703009B publication Critical patent/CN112703009B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980060751.3A 2018-08-17 2019-08-15 治疗急性肺损伤的组合物和方法 Active CN112703009B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
US62/719,217 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Publications (2)

Publication Number Publication Date
CN112703009A CN112703009A (zh) 2021-04-23
CN112703009B true CN112703009B (zh) 2024-06-11

Family

ID=69524874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060751.3A Active CN112703009B (zh) 2018-08-17 2019-08-15 治疗急性肺损伤的组合物和方法

Country Status (11)

Country Link
US (2) US12070483B2 (enExample)
EP (1) EP3836953A4 (enExample)
JP (2) JP7483684B2 (enExample)
KR (1) KR20210046698A (enExample)
CN (1) CN112703009B (enExample)
AU (1) AU2019321654B8 (enExample)
BR (1) BR112021002920A2 (enExample)
CA (1) CA3109798A1 (enExample)
IL (1) IL280868B1 (enExample)
MX (1) MX2021001877A (enExample)
WO (1) WO2020037146A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280868B1 (en) 2018-08-17 2026-05-01 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treating acute lung injury
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
US20240390452A1 (en) * 2023-05-26 2024-11-28 The Trustees Of The University Of Pennsylvania Protective Agent Against Endothelial Dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006301A2 (en) * 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
CN103038253A (zh) * 2010-06-18 2013-04-10 西伯尔科学有限公司 作为用来稳定生物屏障的活性剂的肽
WO2017180546A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
IL280868B1 (en) 2018-08-17 2026-05-01 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treating acute lung injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006301A2 (en) * 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
CN103038253A (zh) * 2010-06-18 2013-04-10 西伯尔科学有限公司 作为用来稳定生物屏障的活性剂的肽
WO2017180546A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Binding sites for interaction of peroxiredoxin 6 with surfactant protein A;Saikumari Y Krishnaiah等;Biochim Biophys Acta.;第1864卷(第4期);摘要、图7、表2 *
Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation;Aron B Fisher等;Antioxidants (Basel);20181205;第7卷(第12期);第181篇 *
Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia;Bavneet Benipal等;Redox Biol.;第321-327页 *
LPS诱导鼠急性肺损伤模型的评价分析;温保强;刘江华;;中国医学创新;20170915(第26期);全文 *

Also Published As

Publication number Publication date
AU2019321654B1 (en) 2025-07-17
JP7822065B2 (ja) 2026-03-02
US20210315964A1 (en) 2021-10-14
EP3836953A4 (en) 2022-06-29
BR112021002920A2 (pt) 2021-05-11
JP2021534184A (ja) 2021-12-09
US20250082715A1 (en) 2025-03-13
EP3836953A1 (en) 2021-06-23
US12070483B2 (en) 2024-08-27
MX2021001877A (es) 2021-07-15
AU2019321654B8 (en) 2025-08-07
AU2019321654A1 (en) 2021-03-18
WO2020037146A1 (en) 2020-02-20
JP2024102207A (ja) 2024-07-30
KR20210046698A (ko) 2021-04-28
IL280868B1 (en) 2026-05-01
IL280868A (en) 2021-04-29
JP7483684B2 (ja) 2024-05-15
CN112703009A (zh) 2021-04-23
CA3109798A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
JP7822065B2 (ja) 急性肺損傷の処置のための組成物および方法
US11400049B2 (en) Pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
CN111529685A (zh) 抗呼吸道病毒感染的鼻腔喷雾制剂
US20230050861A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
KR102511284B1 (ko) 엘라스타제 억제 활성을 갖는 베타-헤어핀 펩티드 모방체 및 이의 에어로졸 투여 형태
US12083165B2 (en) Thymosin alpha 1 for use in treatment of cystic fibrosis
RU2817906C2 (ru) Композиции и способы лечения острого повреждения легких
Groot et al. Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
HK40013569A (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
HK40013569B (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
CN120093755A (zh) 线粒体解偶联剂bam15在制备急性肺损伤/急性呼吸窘迫综合征治疗药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant